Tests engineered T cells against KRAS-mutated pancreatic cancer
Tests modified T cells targeting a KRAS mutation in adults with pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Key facts
- Where
- Stockholm, SwedenSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed metastatic or locally advanced pancreatic cancer (PDAC) whose tumour has a KRAS G12V or KRAS G12D mutation. They also need confirmed HLA genotyping.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed metastatic or locally advanced PDAC, with measurable disease by RECIST 1.1 at the time of first treatment.
- Earlier treatment
- Confirmed clinical benefit from standard-of-care treatment and no disease progression, in the investigator's judgement.
- Biomarker or test result
- KRAS G12V or KRAS G12D mutation confirmed in a tumour biopsy. HLA genotype confirmed with a high-resolution method.
Main reasons for not taking part
- Another cancer besides PDAC
- Current or past brain metastasis
- Known genetic status (for example BRCA, MSI-H) for which other treatments are available
Read by machine on 9 November 2026.
Where in Sweden
- Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anocca AB
- Trial code
- NCT07145450
- Record updated
- 8 June 2026
- Original description
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells and exerting anti- tumour activity in patients with metastatic or locally advanced PDAC.Read full original descriptionShow less
Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR- Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients With Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific combination mutated KRAS and HLA, activating the T cells and exerting anti- tumour activity in patients with metastatic or locally advanced PDAC.
Inclusion: Adult patient (18 years or older) with newly diagnosed metastatic PDAC or locally advance PDAC disease; HLA genotyping confirmed with a high-resolution method; Confirmed KRAS G12V or KRAS G12D mutation in tumour using biopsy sample; Fertile male and female patients must use a highly effective contraceptive method before, during, and for at least 6 months after the last mutKRAS TCR infusion. Acceptable contraception for women includes implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has been vasectomized for at least 6 months. Acceptable contraception for male includes having had a vasectomy for at least 6 months, sexual abstinence, to condoms plus spermicide. Fertile female and male patients must adhere to any treatment-specific pregnancy prevention guidelines for cyclophosphamide (refer to SmPC); Confirmed clinical benefit to SoC treatments and absence of disease progression according to the PI judgement; Measurable disease by RECIST 1.1 criteria at the time of first treatment. Baseline imaging (for example, diagnostic CT of chest/abdomen/pelvis and imaging of the affected extremity or brain, as appropriate), or magnetic resonance imaging (MRI) must be obtained within 8 weeks of the first planned T cell infusion. CT can be substituted for MRI in patients unable to have CT contrast.
Exclusion: Another malignancy other than PDAC; Current or history of brain metastasis; Patient with known genetic status for whom other treatments are available e.g. BRCA, MSI-H.